Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043

NCT03308396 is registered in ClinicalTrials.gov with Ajjai Alva, MD as lead sponsor.

NCT NCT03308396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03308396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Lead sponsor
Ajjai Alva, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 19, 2017
Completion date
December 31, 2023
Enrollment
57 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced kidney cancer, clear cell renal cell carcinoma, kidney cancer